Arterium Corporation launches new antibacterial drug
In July, Arterium Corporation* launched its new antibacterial product Amoxil K-1000 in Ukraine. A broad-spectrum antibiotic targeting most gram-positive and gram-negative microorganisms, the product is the latest addition to Arterium's Amoxil line that already includes powder for injection Amoxil-K and film-coated tablets Amoxil-K 625.
Amoxil K-1000 includes two active ingredients: amoxicillin and clavulanic acid (qualitative content—875 mg to 125 mg). Such proportion of active ingredients helps enhance the antibacterial effect of the drug, prolonging its effect on microorganisms. Amoxil K-1000 enables wider use of amoxicillin and clavulanic acid for doctors to choose an optimal treatment regimen. Antibiotics of this group — co-amoxiclavs (amoxicillin+clavulanic acid) — are often the drugs of choice in the treatment of many bacterial-infection-induced diseases in adults and children: otitis, sinusitis, bronchitis, pneumonia, cystitis and pyelonephritis, skin and soft tissue infection, etc.
The launch was preceded by a clinical trial, which confirmed bioequivalence of Arterium's Amoxil K-1000 to the original drug — Augmentin (GSK, the UK). Manufactured by Arterium Corporation’s Kievmedpreparat, Amoxil K-1000 is available in the form of 1000-mg tablets, 14 tablets per a pack.
*Arterium — Arterium Corporation itself and its parts PJSC Kievmedpreparat and PJSC Galychpharm. This information is intended for medical and pharmaceutical personnel only and shall be used only in relevant professional activities. The data given here is abridged. For full information about the medicinal product, refer to its instructions for medical use. This website is a specialised publication intended for medical and pharmaceutical personnel only.